Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in hospitalized COVID-19 patients
NCT04391309Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing anti-CD14 + SOC with Placebo + SOC (2 arms). Primary endpoint: Time to Clinical Recovery at 28 days. Started Apr 2021; status: terminated.
02
Drugs
atibuclimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04391309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391309.